Literature DB >> 19098933

Editorial and introduction to Asian Journal of Andrology Prostate Cancer special issue.

Roger Kirby, Shu-Jie Xia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19098933      PMCID： PMC3735206          DOI： 10.1038/aja.2008.40

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  10 in total

1.  Radical prostatectomy versus watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Christer Busch; Stig Nordling; Hans Garmo; Juni Palmgren; Hans-Olov Adami; Bo Johan Norlén; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

Review 2.  A selected review and personal experience with robotic prostatectomy: implications for adoption of this new technology in the United Kingdom.

Authors:  M A Goldstraw; K Patil; C Anderson; P Dasgupta; R S Kirby
Journal:  Prostate Cancer Prostatic Dis       Date:  2007-05-22       Impact factor: 5.554

Review 3.  Identification of new genetic risk factors for prostate cancer.

Authors:  Michelle Guy; Zsofia Kote-Jarai; Graham G Giles; Ali Amin Al Olama; Sarah K Jugurnauth; Shani Mulholland; Daniel A Leongamornlert; Stephen M Edwards; Jonathan Morrison; Helen I Field; Melissa C Southey; Gianluca Severi; Jenny L Donovan; Freddie C Hamdy; David P Dearnaley; Kenneth R Muir; Charmaine Smith; Melisa Bagnato; Audrey T Ardern-Jones; Amanda L Hall; Lynne T O'Brien; Beatrice N Gehr-Swain; Rosemary A Wilkinson; Angela Cox; Sarah Lewis; Paul M Brown; Sameer G Jhavar; Malgorzata Tymrakiewicz; Artitaya Lophatananon; Sarah L Bryant; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Christopher J Woodhouse; Alan Thompson; Tim Christmas; Chris Ogden; Cyril Fisher; Charles Jameson; Colin S Cooper; Dallas R English; John L Hopper; David E Neal; Douglas F Easton; Rosalind A Eeles
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

4.  20-year outcomes following conservative management of clinically localized prostate cancer.

Authors:  Peter C Albertsen; James A Hanley; Judith Fine
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

Review 5.  Prostate cancer: diagnosis and staging.

Authors:  Nigel Borley; Mark R Feneley
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

6.  PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.

Authors:  Hiroyuki Nakanishi; Jack Groskopf; Herbert A Fritsche; Viju Bhadkamkar; Amy Blase; S Vikas Kumar; John W Davis; Patricia Troncoso; Harry Rittenhouse; R Joseph Babaian
Journal:  J Urol       Date:  2008-03-18       Impact factor: 7.450

7.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.

Authors:  Simon M Collin; Richard M Martin; Chris Metcalfe; David Gunnell; Peter C Albertsen; David Neal; Freddie Hamdy; Peter Stephens; J Athene Lane; Rollo Moore; Jenny Donovan
Journal:  Lancet Oncol       Date:  2008-04-16       Impact factor: 41.316

9.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

Review 10.  Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.

Authors:  Laurence Klotz
Journal:  Nat Clin Pract Urol       Date:  2005-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.